Lederle R M, Klaus D, Braun B
Dtsch Med Wochenschr. 1980 Sep 19;105(38):1307-12. doi: 10.1055/s-2008-1070861.
The antihypertensive effect of captopril was tested on 19 patients with essential hypertension, WHO grade I or II. In 11 patients blood pressure levels returned to normal over an observation period of 12 weeks at a dose of 3 C 50-150 mg daily (group A). In eight patients with grade II hypertension the absolute blood-pressure reduction was the same, but did not reach normal levels (group B). Although additional intake of propranolol, at a dose of 3 X 40 mg daily, achieved further reduction, normal pressures were still not attained. Initial blood pressure levels were higher and plasma-renin activity lower in patients of group B than of group A. There was a definite rise in plasma-renin activity with captopril, but corresponding to the suppression of plasma-renin in severe hypertension it was less. There was a fall in plasma-aldosterone levels, corresponding to a reduced angiotensin II level as a result of inhibition of the converting enzyme. The fall in plasma-aldosterone activity was less in severe hypertension, although there was the same inhibition of converting enzyme activity in both groups. Normochromic anaemia was noted in three patients, requiring further observation and explanation. No patient developed orthostatic hypotension or reflex tachycardia.
对19例世界卫生组织I级或II级原发性高血压患者进行了卡托普利的降压效果测试。11例患者在12周的观察期内,每日服用3×50 - 150毫克剂量,血压水平恢复正常(A组)。8例II级高血压患者的血压绝对降低幅度相同,但未达到正常水平(B组)。尽管每日额外服用3×40毫克剂量的普萘洛尔可进一步降低血压,但仍未达到正常水平。B组患者的初始血压水平高于A组,血浆肾素活性低于A组。服用卡托普利后血浆肾素活性有明显升高,但与重度高血压患者血浆肾素的抑制情况相比,升高幅度较小。血浆醛固酮水平下降,这与由于转化酶抑制导致的血管紧张素II水平降低相对应。重度高血压患者血浆醛固酮活性下降幅度较小,尽管两组转化酶活性的抑制程度相同。3例患者出现正细胞性贫血,需要进一步观察和解释。未出现患者发生体位性低血压或反射性心动过速。